Prognostic value of pet/ct with 18f-fdg for egfr gene mutations Status evaluation in patients with non-small cell lung cancer

Prognostic value of pet/ct with 18f-fdg for egfr gene mutations status evaluation in patients with non-small cell lung cancer

Leontyev A.V., Rubtsova N.A., Khalimon A.I., Antonevskaya T.L., Khamadeeva G.F., Kuliev M.T., Levshakova A.V., Pylova I.V., Lazutina T.N., Kostin A.A., Kaprin A.D.

The identification of the mutation status of the epidermal growth factor receptor (EGFR) is important for the optimization of treatment in patients

with advanced non-small cell lung cancer.

However, the acquisition of adequate tissues for EGFR mutational

analysis is sometimes not feasible due a number of reasons, also the result can be insignificant when it comes to cellular heterogeneity. PET/CT with 18F-FDG is a highly informative imaging technique used for diagnostics of lung cancer, which can be

used to predict the presence of an EGFR gene mutation.

Previous studies regarding the predictive role of 18F–FDG PET/CT

for EGFR mutations in NSCLC patients are conflicting.

Purpose. To compare the results of numerous studies and determine the prognostic value of various measured parameters 18F-FDG PET/CT. The article also provides general recommendations on the use of given modality at various stages of diagnosis and treatment of patients with non-small cell lung cancer and its advantages over traditional imaging methods.

Moscow P.A. Gertsen Research Institute of Oncology.

Moscow, Russia.

 

Keywords: non-small cell lung cancer, lung cancer, NSCLC, fluorodeoxyglucose, FDG, EGFR, tyrosine kinase inhibitors, PET/CT.

 


Corresponding author:  Leontyev A.V., e-mail: Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

 

For citation: Leontyev A.V., Rubtsova N.A., Khalimon A.I., Antonevskaya T.L., Khamadeeva G.F., Kuliev M.T., Levshakova A.V., Pylova I.V., Lazutina T.N., Kostin A.A., Kaprin A.D. Prognostic value of pet/ct with 18f-fdg for egfr gene mutations status evaluation in patients with non-small cell lung cancer. REJR 2020; 10(1):191-205. DOI:10.21569/2222-7415-2020-10-1-191-205.

.

Received:       10.02.20 Accepted:     26.02.20